Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: Potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment

International Journal of Surgical Oncology

Volumn 2012, Issue , 2012, Pages

  Tanida, Satoshi ^a   Mizoshita, Tsutomu ^a   Ozeki, Keiji ^a   Tsukamoto, Hironobu ^a   Kamiya, Takeshi ^a   Kataoka, Hiromi ^a   Sakamuro, Daitoku ^b   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866153536     PISSN: 20901402     EISSN: 20901410     Source Type: Journal    
DOI: 10.1155/2012/862879     Document Type: Review

References (42)

1. Muñoz N., Franceschi S., Epidemiology of gastric cancer and perspectives for prevention. Salud Publica de Mexico 1997 39 4 318 330 2-s2.0-0030984501 (Pubitemid 27408776)
2. Inoue M., Tsugane S., Epidemiology of gastric cancer in Japan. Postgraduate Medical Journal 2005 81 957 419 424 2-s2.0-22344438694 10.1136/pgmj.2004.029330 (Pubitemid 41002579)
3. Koizumi W., Narahara H., Hara T., Takagane A., Akiya T., Takagi M., Miyashita K., Nishizaki T., Kobayashi O., Takiyama W., Toh Y., Nagaie T., Takagi S., Yamamura Y., Yanaoka K., Orita H., Takeuchi M., S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. The Lancet Oncology 2008 9 3 215 221 2-s2.0-40749153540 10.1016/S1470-2045(08)70035-4
4. Rino Y., Yukawa N., Murakami H., Wada N., Yamada R., Hayashi T., Sato T., Ohshima T., Masuda M., Imada T., A phase II study of S-1 monotherapy as a first-line combination therapy of S-1 plus cisplatin as a second-line therapy, and weekly paclitaxel monotherapy as a third-line therapy in patients with advanced gastric carcinoma: a second report. Clinical Medicine Insights 2010 4 1 10 2-s2.0-77951495714
5. Pyndiah S., Tanida S., Ahmed K. M., Cassimere E. K., Choe C., Sakamuro D., c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Science Signaling 2011 4 166, article ra19 2-s2.0-79953251340 10.1126/scisignal.2001556
6. Sedletska Y., Giraud-Panis M. J., Malinge J. M., Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Current Medicinal Chemistry 2005 5 3 251 265 2-s2.0-18544370041 10.2174/1568011053765967 (Pubitemid 40655276)
7. De Laat W. L., Jaspers N. G. J., Hoeijmakers J. H. J., Molecular mechanism of nucleotide excision repair. Genes and Development 1999 13 7 768 785 2-s2.0-0033118354 (Pubitemid 29169836)
8. Rosenberg B., Van Camp L., Krigas T., Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965 205 4972 698 699 2-s2.0-37049053957 10.1038/205698a0
9. Rosenberg B., VanCamp L., The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Research 1970 30 6 1799 1802 2-s2.0-0014803443
10. Cvitkovic E., Misset J. L., Chemotherapy for ovarian cancer. The New England Journal of Medicine 1996 334 19 1269 1270 2-s2.0-0030576186
11. Eastman A., The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacology and Therapeutics 1987 34 2 155 166 2-s2.0-0023628351 (Pubitemid 17149009)
12. Kelland L. R., New platinum antitumor complexes. Critical Reviews in Oncology/Hematology 1993 15 3 191 219 2-s2.0-0027748224 10.1016/1040-8428(93) 90042-3 (Pubitemid 24047767)
13. Donahue B. A., Augot M., Bellon S. F., Treiber D. K., Toney J. H., Lippard S. J., Essigmann J. M., Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry 1990 29 24 5872 5880 2-s2.0-0025357981 10.1021/bi00476a032 (Pubitemid 20192462)
14. Fink D., Aebi S., Howell S. B., The role of DNA mismatch repair in drug resistance. Clinical Cancer Research 1998 4 1 1 6 2-s2.0-0031906084 (Pubitemid 28062870)
15. Chaney S. G., Vaisman A., Specificity of platinum-DNA adduct repair. Journal of Inorganic Biochemistry 1999 77 1-2 71 81 2-s2.0-0033390413 10.1016/S0162-0134(99)00149-X (Pubitemid 30089085)
16. Damia G., Filiberti L., Vikhanskaya F., Carrassa L., Taya Y., D'Incalci M., Broggini M., Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 2001 3 1 10 16 2-s2.0-0035093544 (Pubitemid 32201605)
17. Zhao H., Piwnica-Worms H., ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Molecular and Cellular Biology 2001 21 13 4129 4139 2-s2.0-0034967556 10.1128/MCB.21.13.4129-4139.2001 (Pubitemid 32565295)
18. Appella E., Anderson C. W., Post-translational modifications and activation of p53 by genotoxic stresses. European Journal of Biochemistry 2001 268 10 2764 2772 2-s2.0-0034818446 10.1046/j.1432-1327.2001.02225.x (Pubitemid 32862957)
19. Persons D. L., Yazlovitskaya E. M., Pelling J. C., Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. Journal of Biological Chemistry 2000 275 46 35778 35785 2-s2.0-0034680896 10.1074/jbc.M004267200
20. Catani M. V., Costanzo A., Savini I., Levrero M., De Laurenzi V., Wang J. Y. J., Melino G., Avigliano L., Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: implications for the cellular response to DNA damage. Biochemical Journal 2002 364 2 441 447 2-s2.0-0036606443 10.1042/BJ20011713 (Pubitemid 34620804)
21. Gong J., Costanzo A., Yang H. Q., Mellno G., Kaelin W. G., Levrero M., Wang J. Y. J., The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999 399 6738 806 809 2-s2.0-0033600234 10.1038/21690 (Pubitemid 29293179)
22. Tsai K. K. C., Yuan Z. M., c-Abl stabilizes p73 by a phosphorylation- augmented interaction. Cancer Research 2003 63 12 3418 3424 2-s2.0-0038745373 (Pubitemid 36735903)
23. Viktorsson K., Ekedahl J., Lindebro M. C., Lewensohn R., Zhivotovsky B., Linder S., Shoshan M. C., Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line. Experimental Cell Research 2003 289 2 256 264 2-s2.0-0141565270 10.1016/S0014-4827(03)00264-7 (Pubitemid 37117411)
24. Adams J. M., Ways of dying: multiple pathways to apoptosis. Genes and Development 2003 17 20 2481 2495 2-s2.0-0142027948 10.1101/gad.1126903 (Pubitemid 37271417)
25. Shi L., Nishioka W. K., Th'ng J., Bradbury E. M., Litchfield D. W., Greenberg A. H., Premature p34(cdc2) activation required for apoptosis. Science 1994 263 5150 1143 1145 2-s2.0-0028178508
26. Shapiro G. I., Harper J. W., Anticancer drug targets: cell cycle and checkpoint control. Journal of Clinical Investigation 1999 104 12 1645 1653 2-s2.0-0033399453 (Pubitemid 30053178)
27. Andrews P. A., Velury S., Mann S. C., Howell S. B., cis- Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Research 1988 48 1 68 73 2-s2.0-0023875417 (Pubitemid 18030332)
28. Gately D. P., Howell S. B., Cellular accumulation of the anticancer agent cisplatin: a review. British Journal of Cancer 1993 67 6 1171 1176 2-s2.0-0027233829 (Pubitemid 23172848)
29. Kool M., De Haas M., Scheffer G. L., Scheper R. J., Van Eijk M. J. T., Juijn J. A., Baas F., Borst P., Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Research 1997 57 16 3537 3547 2-s2.0-0030841332 (Pubitemid 27355505)
30. Koike K., Kawabe T., Tanaka T., Toh S., Uchiumi T., Wada M., Akiyama S. I., Ono M., Kuwano M., A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Research 1997 57 24 5475 5479 2-s2.0-0031468814 (Pubitemid 28006750)
31. Nakayama K., Kanzaki A., Ogawa K., Miyazaki K., Neamati N., Takebayashi Y., Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. International Journal of Cancer 2002 101 5 488 495 2-s2.0-0037057531 10.1002/ijc.10608
32. Sakamoto M., Kondo A., Kawasaki K., Goto T., Sakamoto H., Miyake K., Koyamatsu Y., Akiya T., Iwabuchi H., Muroya T., Ochiai K., Tanaka T., Kikuchi Y., Tenjin Y., Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Human Cell 2001 14 4 305 315 2-s2.0-0035750278
33. Lee K. B., Parker R. J., Bohr V., Cornelison T., Reed E., Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993 14 10 2177 2180 2-s2.0-0027372625 (Pubitemid 23311452)
34. Dabholkar M., Vionnet J., Bostick-Bruton F., Jing Jie Yu, Reed E., Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. Journal of Clinical Investigation 1994 94 2 703 708 2-s2.0-0028141961 (Pubitemid 24251002)
35. Gowen L. C., Avrutskaya A. V., Latour A. M., Koller B. H., Leadon S. A., BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998 281 5379 1009 1012 2-s2.0-0032516654 (Pubitemid 28399254)
36. Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., Ohmoto H., Node K., Yoshino K., Ishiguro H., Asanuma H., Sanada S., Matsumura Y., Takeda H., Beppu S., Tada M., Hori M., Higashiyama S., Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nature Medicine 2002 8 1 35 40 2-s2.0-0036152858 10.1038/nm0102-35 (Pubitemid 34101726)
37. Tanida S., Joh T., Itoh K., Kataoka H., Sasaki M., Ohara H., Nakazawa T., Nomura T., Kinugasa Y., Ohmoto H., Ishiguro H., Yoshino K., Higashiyama S., Itoh M., The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 2004 127 2 559 569 2-s2.0-4143111325 10.1053/j.gastro.2004.05.017 (Pubitemid 39091904)
38. Zhou B. P., Liao Y., Xia W., Spohn B., Lee M. H., Hung M. C., Cytoplasmic localization of p21 CIP1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biology 2001 3 3 245 252 2-s2.0-0034745353 10.1038/35060032 (Pubitemid 32201319)
39. Sakamuro D., Elliott K. J., Wechsler-Reya R., Prendergast G. C., BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nature Genetics 1996 14 1 69 77 2-s2.0-0029741917 10.1038/ng0996-69 (Pubitemid 26301549)
40. Ge K., Duhadaway J., Sakamuro D., Wechsler-Reya R., Reynolds C., Prendergast G. C., Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. International Journal of Cancer 2000 85 376 383 (Pubitemid 30030412)
41. Meyer-Ficca M. L., Meyer R. G., Jacobson E. L., Jacobson M. K., Poly(ADP-ribose) polymerases: managing genome stability. International Journal of Biochemistry and Cell Biology 2005 37 5 920 926 2-s2.0-14644393675 10.1016/j.biocel.2004.09.011 (Pubitemid 40311734)
42. Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., Möröy T., Bartek J., Massagué J., Hänel F., Eilers M., Repression of p15INK4b expression by Myc through association with Miz-1. Nature Cell Biology 2001 3 4 392 399 2-s2.0-0034744957 10.1038/35070076 (Pubitemid 32288447)